Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.

Autor:	Joshi AD; Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Botham RC; Department of Chemistry, University of Illinois Urbana-Champaign, Urbana, IL, USA., Schlein LJ; Department of Pathobiology, University of Illinois Urbana-Champaign, Urbana, IL, USA., Roth HS; Department of Chemistry, University of Illinois Urbana-Champaign, Urbana, IL, USA., Mangraviti A; Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Borodovsky A; Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Tyler B; Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Joslyn S; VetCT Australia, Fremantle WA, Australia., Looper JS; Department of Veterinary Clinical Sciences, Louisiana State University, Baton Rouge, LA, USA., Podell M; Department of Neurology, MedVet Chicago, Chicago, IL, USA., Fan TM; Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA., Hergenrother PJ; Department of Chemistry, University of Illinois Urbana-Champaign, Urbana, IL, USA., Riggins GJ; Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2017 Jul 07; Vol. 8 (46), pp. 80124-80138. Date of Electronic Publication: 2017 Jul 07 (Print Publication: 2017).
DOI:	10.18632/oncotarget.19085
Abstrakt:	Purpose: Glioblastoma is a deadly brain cancer with a median survival time of ∼15 months. Ionizing radiation plus the DNA alkylator temozolomide (TMZ) is the current standard therapy. PAC-1, a procaspase-3 activating small molecule, is blood-brain barrier penetrant and has previously demonstrated ability to synergize with diverse pro-apoptotic chemotherapeutics. We studied if PAC-1 could enhance the activity of TMZ, and whether addition of PAC-1 to standard treatment would be feasible in spontaneous canine malignant gliomas. Experimental Design: Using cell lines and online gene expression data, we identified procaspase-3 as a potential molecular target for most glioblastomas. We investigated PAC-1 as a single agent and in combination with TMZ against glioma cells in culture and in orthotopic rodent models of glioma. Three dogs with spontaneous gliomas were treated with an analogous human glioblastoma treatment protocol, with concurrent PAC-1. Results: Procaspase-3 is expressed in gliomas, with higher gene expression correlating with increased tumor grade and decreased prognosis. PAC-1 is cytotoxic to glioma cells in culture and active in orthotopic rodent glioma models. PAC-1 added to TMZ treatments in cell culture increases apoptotic death, and the combination significantly increases survival in orthotopic glioma models. Addition of PAC-1 to TMZ and radiation was well-tolerated in 3 out of 3 pet dogs with spontaneous glioma, and partial to complete tumor reductions were observed. Conclusions: Procaspase-3 is a clinically relevant target for treatment of glioblastoma. Synergistic activity of PAC-1/TMZ in rodent models and the demonstration of feasibility of the combined regime in canine patients suggest potential for PAC-1 in the treatment of glioblastoma. Competing Interests: CONFLICTS OF INTEREST Paul Hergenrother, Timothy Fan, Avadhut Joshi, Rachel Botham, Howard Roth and Gregory Riggins have a financial interest in the compound PAC-1 through intellectual property. Authors with a financial interest in PAC-1 via Vanquish Oncology are Paul Hergenrother, Timothy Fan and Gregory Riggins. These potential conflict of interests are managed through the respective university's conflict of interest policy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu